Koelling Sebastian, Miosge Nicolai
Georg August University, Tissue Regeneration Work Group, Department of Prosthodontics, Abteilung Prothetik im Zentrum ZMK, Robert-Koch-Str. 40, Goettingen, D-37075, Germany.
Expert Opin Biol Ther. 2009 Nov;9(11):1399-405. doi: 10.1517/14712590903246370.
Enhancing the regeneration potential of hyaline cartilage tissue remains a great challenge. During embryonic development, some of the cells of the inner cell mass will turn into the mesoderm. This will be the founder of the mesenchymal cells in connective tissues of adult life, such as bone, tendon, muscle, and cartilage. Some of these embryonic mesenchymal cells are believed not to differentiate, but reside in each of the tissues. These are now collectively described as adult mesenchymal stem cells, which are thought to be capable of repairing injured tissue. We will briefly summarize the current knowledge about stem cell-related cells in cartilage tissue and carefully discuss the potential of the cell population we described recently as a starting-point for a regenerative therapy for osteoarthritis. We found that repair tissue from human articular cartilage during the late stages of osteoarthritis harbors a unique progenitor cell population, termed chondrogenic progenitor cells (CPC). These exhibit stem cell characteristics combined with a high chondrogenic potential. They offer new insights into the biology of progenitor cells and may be relevant in the development of novel therapeutic approaches for a cell-based therapy for late stages of osteoarthritis.
增强透明软骨组织的再生潜能仍然是一项巨大挑战。在胚胎发育过程中,内细胞团的一些细胞会转变为中胚层。这将成为成年后结缔组织中间充质细胞的来源,如骨骼、肌腱、肌肉和软骨。据信这些胚胎间充质细胞中的一些不会分化,而是存在于每种组织中。现在这些细胞被统称为成人间充质干细胞,被认为能够修复受损组织。我们将简要总结目前关于软骨组织中与干细胞相关细胞的知识,并仔细讨论我们最近描述的细胞群体作为骨关节炎再生治疗起点的潜力。我们发现,骨关节炎晚期人类关节软骨的修复组织中存在一种独特的祖细胞群体,称为软骨生成祖细胞(CPC)。这些细胞表现出干细胞特征并具有高软骨生成潜能。它们为祖细胞生物学提供了新见解,可能与开发用于骨关节炎晚期基于细胞治疗的新治疗方法相关。
Expert Opin Biol Ther. 2009-11
Novartis Found Symp. 2003
Transplant Proc. 2005-11
Ann Anat. 2008-11-20
Curr Opin Investig Drugs. 2002-7
J Intern Med. 2009-10
Panminerva Med. 2008-3
Orv Hetil. 2005-5-29
Front Bioeng Biotechnol. 2022-6-6
Front Bioeng Biotechnol. 2022-5-27
Materials (Basel). 2022-3-7